Condition
Devic's Disease
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed4
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03062579Phase 1Completed
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
NCT00787722Phase 1CompletedPrimary
Hematopoietic Stem Cell Transplant in Devic's Disease
NCT03829566Phase 2Withdrawn
Autologous Transplant To End NMO Spectrum Disorder
NCT02249676Phase 2Completed
Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
NCT00904826Phase 1Completed
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Showing all 5 trials